Fosun Pharma has successfully issued China's pioneering medium- to long-term scientific and technological innovation bond tailored for the private pharmaceutical industry, amounting to RMB 1 billion over a span of 2 years, with a coupon rate of 2.70%. This bond offering was met with enthusiastic subscriptions from numerous financial institutions and received the backing of China Bond Insurance Investment Co., Ltd. The proceeds will be allocated to bolster Fosun Pharma's strategic positioning in pivotal scientific and technological innovation domains, expedite the commercialization of innovative achievements, and elevate its competitive edge within the global healthcare landscape. This issuance underscores Fosun Pharma's proactive alignment with national policies aimed at fostering private enterprise development, while simultaneously refining the company's financing costs and debt structure. Committed to innovation as its core driver, Fosun Pharma has garnered notable accomplishments in the realm of innovative drugs in recent years. Looking ahead, the company vows to further deepen its innovative transformation and remains dedicated to delivering superior, more accessible products and services.